Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
about
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptorQSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forestHomology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.Anchor-based classification and type-C inhibitors for tyrosine kinases.Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.Epidermal growth factor receptor inhibitors: a patent review (2010 - present).Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups.Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.Synthesis and Evaluation of Biological and Antitumor Activities of Tetrahydrobenzothieno[2,3-d]Pyrimidine Derivatives as Novel Inhibitors of FGFR1.CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints.Design, Synthesis, and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives as Anti-Inflammatory Agents.Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors.Synthesis and Bioevaluation of Thieno[2,3-d]pyrimidinone Derivatives as Potential Tumor Cell Growth Inhibitors
P2860
Q27677383-A302C528-8C26-4DB6-B910-3F125891357EQ28544930-6A20044A-A0C3-4CAB-B7A3-644ACCB6BDC8Q35676486-D0712422-BD16-4F95-AF8F-FBB06BC2B72DQ35745479-745E9500-4357-4267-9B6A-386587A4C479Q36567573-4E444C52-4F3B-4BAD-871C-0ABC392FF1B7Q38175432-5E8799FE-CFD4-47A0-821A-ECF243B3BFB6Q38770450-966A91CC-EA02-4152-9492-8A73B17F7217Q39079553-8F3278A3-6559-4E8F-872A-8F44F86E9CE8Q39126918-469E0366-4525-4093-ACFF-46D49123BE5FQ40313976-D96E5676-4A18-4DD8-85F6-77303E758DC5Q43816076-5215EF4E-6B1F-45F0-AF08-B28A0A13E9F7Q47403944-2FC265D9-6C9B-473D-AA83-61BF14AEC9CBQ47614531-54680431-4E9D-42BB-8F1A-FB40B2023313Q50862064-12721EF7-BF8A-4F2C-8C8E-BE2F5422B37FQ59010648-265CFF6F-6129-4ABA-AD2E-B8C08C6427BA
P2860
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Design and synthesis of tetrah ...... tor group for maximal potency.
@en
Design and synthesis of tetrah ...... tor group for maximal potency.
@nl
type
label
Design and synthesis of tetrah ...... tor group for maximal potency.
@en
Design and synthesis of tetrah ...... tor group for maximal potency.
@nl
prefLabel
Design and synthesis of tetrah ...... tor group for maximal potency.
@en
Design and synthesis of tetrah ...... tor group for maximal potency.
@nl
P2093
P356
P1476
Design and synthesis of tetrah ...... ptor group for maximal potency
@en
P2093
Chang-Ying Chu
Chia-Hsien Wu
Ching-Ping Chen
Chiung-Tong Chen
Chun-Chen Liao
Chun-Hwa Chen
Chun-Yu Chang
Hsing-Pang Hsieh
Hui-Yi Shiao
P304
P356
10.1021/JM100607R
P407
P577
2010-10-01T00:00:00Z